In a bilateral subcutaneous tumor model, significant additional antitumor effects (OBP-702 vs Butyrate + OBP-702) were observed on the OBP-702 un-injected side, whereas no significant differences were observed in the analyses of antitumor immunity such as CD8, IFN-γ, and Granzyme B. In an orthotopic tumor model, significant additional effects were observed only in the analysis of Granzyme B in the liver metastases, which may be attributed to OBP-702 monotherapy being too potent to allow for additional effects of butyrate, as suggested by the IVIS imaging results. The gene discussed is GZMB; the disease is neoplasm.